search
Back to results

Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease (RAPID)

Primary Purpose

Peripheral Arterial Disease

Status
Completed
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
CorPath 200 System
Sponsored by
Corindus Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Arterial Disease focused on measuring Peripheral Arterial Disease, Critical Limb Ischemia, Claudication, Percutaneous Vascular Intervention, Peripheral Vascular Intervention

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • General Inclusion

    1. At least 18 years of age;
    2. Symptomatic disease: presence of critical limb ischemia (including tissue loss or rest pain), or lifestyle-limiting claudication requiring intervention in iliac and/or superficial femoral arteries;
    3. The subject or the legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent.
  • Angiographic Inclusion

Presence of superficial femoral artery and/or iliac stenosis (>50%) or occlusion of up to 50 mm in length as determined by angiogram prior to index interventional procedure.

Exclusion Criteria:

  • General Exclusion

    1. Failure/inability/unwillingness to provide informed consent;
    2. Target vessel has been previously treated with bypass;
    3. Has an abdominal aortic aneurysm contiguous with the iliac artery target lesion;
    4. Has contraindication to anticoagulation;
    5. Has bleeding or a hypercoagulability disorder;
    6. Thrombocytopenia;
    7. Elevated international normalized ratio (>1.5);
    8. Elevated serum creatinine (≥2.5 mg/dL);
    9. Active infection;
    10. Contraindication to contrast; or
    11. Enrolled in concurrent clinical study.
  • Angiographic Exclusion

    1. Target vessel:

      1. shows evidence of previous dissection or perforation, or
      2. has adjacent acute thrombus;
    2. Lesion is highly calcified;
    3. Lesion requires use of any atherectomy device during the procedure;
    4. Has a pre-existing target artery aneurysm or perforation or dissection of the target artery prior to initiation of the interventional procedure.

Sites / Locations

  • Medizinische Univeristät Graz

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CorPath 200 System

Arm Description

CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention.

Outcomes

Primary Outcome Measures

Device Technical Success
Number of lesions for which there was technical success" as accurate and appropriate.
Adverse Events
No device-related serious adverse events during the procedure.

Secondary Outcome Measures

Clinical Procedural Success
Defined as <50% residual stenosis in all CorPath 200 System treated lesions at the completion of the interventional procedure (without an unplanned switch to the manual procedure) in the absence of device-related SAE, either within twenty-four (24) hours of the procedure or prior to hospital discharge, whichever occurs first.
Fluoroscopy Time
As recorded by an X-ray system utilized during the procedure.
Contrast Volume
Total amount of contrast used during CorPath procedure.
Total Procedure Time
Defined as the time measured from the insertion of the hemostasis sheath until procedure complete (guide catheter removed).
Interventional Procedure Time
Defined as the time measured from the insertion of the guide catheter until the removal of the guide catheter.

Full Information

First Posted
February 20, 2015
Last Updated
March 18, 2019
Sponsor
Corindus Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02371785
Brief Title
Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease
Acronym
RAPID
Official Title
Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
February 3, 2015 (Actual)
Primary Completion Date
April 28, 2015 (Actual)
Study Completion Date
May 22, 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Corindus Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the performance of the CorPath 200 System to deliver guide wires and balloons to blockages in the arteries of the leg.
Detailed Description
The CorPath 200 System is currently marketed for remotely delivering guide wires, balloons and stents to blockages in the coronary arteries. This study will evaluate the feasibility of CorPath 200 System to deliver guide wires and balloons to blockages in non-coronary arteries. Guide wires and balloons are delivered to blockages in the lower limbs manually by doctors.If this study shows that guide wires and balloons can be safely delivered to blockages in the lower limbs, then it will be an alternative for physicians.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease
Keywords
Peripheral Arterial Disease, Critical Limb Ischemia, Claudication, Percutaneous Vascular Intervention, Peripheral Vascular Intervention

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CorPath 200 System
Arm Type
Experimental
Arm Description
CorPath 200 System for remote delivery and manipulation of guidewires and balloon catheters during percutaneous vascular intervention.
Intervention Type
Device
Intervention Name(s)
CorPath 200 System
Intervention Description
Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
Primary Outcome Measure Information:
Title
Device Technical Success
Description
Number of lesions for which there was technical success" as accurate and appropriate.
Time Frame
Procedure
Title
Adverse Events
Description
No device-related serious adverse events during the procedure.
Time Frame
Procedure
Secondary Outcome Measure Information:
Title
Clinical Procedural Success
Description
Defined as <50% residual stenosis in all CorPath 200 System treated lesions at the completion of the interventional procedure (without an unplanned switch to the manual procedure) in the absence of device-related SAE, either within twenty-four (24) hours of the procedure or prior to hospital discharge, whichever occurs first.
Time Frame
24-hours
Title
Fluoroscopy Time
Description
As recorded by an X-ray system utilized during the procedure.
Time Frame
Procedure
Title
Contrast Volume
Description
Total amount of contrast used during CorPath procedure.
Time Frame
Procedure
Title
Total Procedure Time
Description
Defined as the time measured from the insertion of the hemostasis sheath until procedure complete (guide catheter removed).
Time Frame
Procedure
Title
Interventional Procedure Time
Description
Defined as the time measured from the insertion of the guide catheter until the removal of the guide catheter.
Time Frame
Procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: General Inclusion At least 18 years of age; Symptomatic disease: presence of critical limb ischemia (including tissue loss or rest pain), or lifestyle-limiting claudication requiring intervention in iliac and/or superficial femoral arteries; The subject or the legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent. Angiographic Inclusion Presence of superficial femoral artery and/or iliac stenosis (>50%) or occlusion of up to 50 mm in length as determined by angiogram prior to index interventional procedure. Exclusion Criteria: General Exclusion Failure/inability/unwillingness to provide informed consent; Target vessel has been previously treated with bypass; Has an abdominal aortic aneurysm contiguous with the iliac artery target lesion; Has contraindication to anticoagulation; Has bleeding or a hypercoagulability disorder; Thrombocytopenia; Elevated international normalized ratio (>1.5); Elevated serum creatinine (≥2.5 mg/dL); Active infection; Contraindication to contrast; or Enrolled in concurrent clinical study. Angiographic Exclusion Target vessel: shows evidence of previous dissection or perforation, or has adjacent acute thrombus; Lesion is highly calcified; Lesion requires use of any atherectomy device during the procedure; Has a pre-existing target artery aneurysm or perforation or dissection of the target artery prior to initiation of the interventional procedure.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marianne Brodmann, M.D.
Organizational Affiliation
Medizinische Universität Graz
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medizinische Univeristät Graz
City
Graz
ZIP/Postal Code
A-8036
Country
Austria

12. IPD Sharing Statement

Learn more about this trial

Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease

We'll reach out to this number within 24 hrs